Pfizer COVID Vaccine Shows 90.7% Efficacy In children: Report
Pfizer's clinical trial in children from the age of 5 to 11 years was not primarily designed to measure efficacy against the virus. Instead, it compared the amount of neutralizing antibodies induced by the vaccine in children to the response of older recipients in the adult trials. Based on the results the company said that their COVID-19 vaccine induced a robust immune response in children.